Document is current
Any future updates will be listed below
-
Authors
Beaudoin, Francesca L.
An, Xinming
Basu, Archana
Ji, Yinyao http://orcid.org/0000-0002-5548-2508
Liu, Mochuan
Kessler, Ronald C. http://orcid.org/0000-0003-4831-2305
Doughtery, Robert F.
Zeng, Donglin
Bollen, Kenneth A.
House, Stacey L.
Stevens, Jennifer S. http://orcid.org/0000-0003-4674-0314
Neylan, Thomas C. http://orcid.org/0000-0002-1572-2626
Clifford, Gari D.
Jovanovic, Tanja http://orcid.org/0000-0002-6456-0053
Linnstaedt, Sarah D. http://orcid.org/0000-0001-5295-7072
Germine, Laura T. http://orcid.org/0000-0001-8690-8412
Rauch, Scott L.
Haran, John P.
Storrow, Alan B.
Lewandowski, Christopher http://orcid.org/0000-0001-8297-0024
Musey, Paul I. Jr.
Hendry, Phyllis L.
Sheikh, Sophia http://orcid.org/0000-0003-1939-3126
Jones, Christopher W.
Punches, Brittany E. http://orcid.org/0000-0002-7546-1966
Kurz, Michael C.
Swor, Robert A.
Murty, Vishnu P.
McGrath, Meghan E.
Hudak, Lauren A.
Pascual, Jose L. http://orcid.org/0000-0002-1613-7912
Datner, Elizabeth M.
Chang, Anna M. http://orcid.org/0000-0002-6494-9843
Pearson, Claire
Peak, David A.
Merchant, Roland C.
Domeier, Robert M.
Rathlev, Niels K.
Neil, Brian J. O’
Sergot, Paulina
Sanchez, Leon D. http://orcid.org/0000-0002-8807-0913
Bruce, Steven E. http://orcid.org/0000-0002-5807-4382
Baker, Justin T. http://orcid.org/0000-0002-6629-2195
Joormann, Jutta
Miller, Mark W. http://orcid.org/0000-0001-6393-8563
Pietrzak, Robert H.
Barch, Deanna M. http://orcid.org/0000-0003-1693-8506
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Sheridan, John F.
Smoller, Jordan W. http://orcid.org/0000-0002-0381-6334
Harte, Steven E.
Elliott, James M.
Koenen, Karestan C. http://orcid.org/0000-0003-2978-7655
Ressler, Kerry J. http://orcid.org/0000-0002-5158-1103
McLean, Samuel A. http://orcid.org/0000-0001-9482-3582
- License Information
-
More Information
Article History
Received: 29 June 2021
Revised: 25 October 2022
Accepted: 14 December 2022
First Online: 7 January 2023
Competing interests
: In the past 3 years, Dr. Kessler was a consultant for Datastat, Inc., RallyPoint Networks, Inc., Sage Pharmaceuticals, and Takeda. In the last three years, Dr. Clifford has received research funding from the NSF, NIH, and LifeBell AI, and unrestricted donations from AliveCor, Amazon Research, the Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, the Gates Foundation, Google, One Mind Foundation, and Samsung Research. Dr. Clifford has a financial interest in AliveCor and receives unrestricted funding from the company. He also is the CTO of MindChild Medical and CSO of LifeBell AI and has ownership in both companies. These relationships are unconnected to the current work. Dr. Germine is on the scientific advisory board of the nonprofit Sage Bionetworks, for which she receives a small honorarium. Dr. Sheikh has received funding from the Florida Medical Malpractice Joint Underwriter’s Association Dr. Alvin E. Smith Safety of Healthcare Services Grant, Allergan Foundation, the NIH/NIA-funded Jacksonville Aging Studies Center (JAX-ASCENT; R33AG05654), the Substance Abuse and Mental Health Services Administration (1H79TI083101-01), and the Florida Blue Foundation. Dr. Jones reports no direct conflicts related to this paper and no ongoing conflicts. He has been an investigator on studies funded by Hologic Inc., Janssen, and AstraZeneca, for which his department has received research funding. Over the past 3 years, Dr. Pizzagalli has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. Dr. Elliott reports support from the National Institutes of Health (NIH) through Grant Numbers R01HD079076 & R03HD094577, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Center for Medical Rehabilitation Research, and consulting fees (<$15,000 per annum) from Orofacial Therapeutics, LLC. Dr. Ressler has served on advisory boards for Takeda, Resilience Therapeutics, Janssen, and Verily/Google. His research has been sponsored by Alkermes and Brainsway and he has worked as a consultant for Alkermes. Dr. McLean served as a consultant for Walter Reed and for Arbor Medical Innovations. The remaining authors declare no competing interests.
